What is Flow Neuroscience?
Based in Malmoe, Sweden, Flow Neuroscience operates at the intersection of medical device engineering and digital health. The company provides a comprehensive solution for depression management, integrating a proprietary tDCS headset with a behavioral therapy application. By targeting the dorsolateral prefrontal cortex, the device aims to modulate neural activity, offering a non-pharmacological alternative for patients. This dual-modality approach—combining physical stimulation with cognitive behavioral therapy—positions Flow Neuroscience as a leader in the burgeoning field of neuro-digital therapeutics, addressing a critical gap in accessible, evidence-based mental health interventions.
How much funding has Flow Neuroscience raised?
Flow Neuroscience has raised a total of $11.9M across 3 funding rounds:
Angel/Seed
$1.1M
Other Financing Round
$1.5M
Series A
$9.3M
Angel/Seed (2018): $1.1M with participation from SOSV and Khosla Ventures
Other Financing Round (2019): $1.5M led by Khosla Ventures
Series A (2021): $9.3M supported by Swiss Health Ventures, Zühlke Ventures, and Khosla Ventures
Key Investors in Flow Neuroscience
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, with a strong focus on health and enterprise innovation.
Swiss Health Ventures
A specialized investment firm focusing on the healthcare sector, providing capital to companies that demonstrate significant potential for clinical impact.
Zühlke Ventures
An investment entity that supports high-tech startups, often providing the necessary resources to bridge the gap between technical innovation and market commercialization.
What's next for Flow Neuroscience?
With the recent capital infusion, Flow Neuroscience is poised to accelerate its clinical validation efforts and expand its market footprint. The strategic focus will likely center on scaling the distribution of its medical device, enhancing the efficacy of its companion app, and navigating the complex regulatory landscapes of international healthcare markets. As the firm transitions into a more mature phase of its lifecycle, the emphasis will shift toward long-term patient outcomes and the integration of its technology into standard clinical care pathways. Investors are closely watching how the company leverages this financing to solidify its competitive advantage in the global mental health technology sector.
See full Flow Neuroscience company page
